José Ursic-Bedoya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
José Ursic-Bedoya has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Georges-Philippe Pageaux
Hepato-gastroenterology Department, CHU Saint Eloi, Montpellier University
7 shared publications - Damien Gregoire
Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
5 shared publications Eric Assenat
Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
5 shared publicationsAstrid Herrero
Department of Hepato-Biliary and Pancreatic Surgery and Liver Transplantation, Montpellier University Hospital, Montpellier, France
4 shared publications- Boris Guiu
Department of Radiology, St-Eloi University Hospital, Montpellier, France
4 shared publications Stéphanie Faure
Department of Hepatogastroenterology, Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Montpellier, France
4 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Evaluation of available scoring systems in liver transplantation for severe acute-on-chronic liver failure (ACLF)
The Transplantation for ACLF-3 Model (TAM) and Sundaram ACLF-LT-Mortality score (SALT-M) have been proposed to help select liver transplantation (LT) candidates with acute-on-chronic liver failure (ACLF) to optimize post-LT outcomes. We assessed the performance and clinical utility of these scores and their components on a large retrospective international multicenter study. All patients transplanted in the context of ACLF grade 3 (n=336) from 9 international cohorts (2008–2024) were included in the study. The primary endpoint was 1-year post-LT survival. Score discrimination, calibration, and clinical utility using decision-curve (net benefit) analysis were assessed. The 1-year post-LT survival rate was 75.3%. Both TAM (OR 1.91, p =0.0001) and SALT-M (OR 1.09, p 25 (46.9% vs. 78.7%). Respiratory failure (PaO 2 /FiO 2 ≤200) was associated with 1-year post-LT mortality, whereas other variables included in the original scores, diabetes, BMI, and leukocyte count, did not demonstrate significant prognostic value in this cohort. In this large multicenter study, TAM and SALT-M were associated with post-LT mortality but demonstrated limited discriminative accuracy. Candidate high-risk thresholds (TAM ≥3, SALT-M >25) may help identify a small subset of patients with markedly poor post-LT outcomes. However, given their modest performance, these scores should support, not replace, multidisciplinary decision-making, and their applicability should be evaluated in a prospective fashion.
- 8 September 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Open AccessEvaluation of available scoring systems in liver transplantation for severe acute-on-chronic liver failure (ACLF)
The Transplantation for ACLF-3 Model (TAM) and Sundaram ACLF-LT-Mortality score (SALT-M) have been proposed to help select liver transplantation (LT) candidates with acute-on-chronic liver failure (ACLF) to optimize post-LT outcomes. We assessed the performance and clinical utility of these scores and their components on a large retrospective international multicenter study. All patients transplanted in the context of ACLF grade 3 (n=336) from 9 international cohorts (2008–2024) were included in the study. The primary endpoint was 1-year post-LT survival. Score discrimination, calibration, and clinical utility using decision-curve (net benefit) analysis were assessed. The 1-year post-LT survival rate was 75.3%. Both TAM (OR 1.91, p =0.0001) and SALT-M (OR 1.09, p 25 (46.9% vs. 78.7%). Respiratory failure (PaO 2 /FiO 2 ≤200) was associated with 1-year post-LT mortality, whereas other variables included in the original scores, diabetes, BMI, and leukocyte count, did not demonstrate significant prognostic value in this cohort. In this large multicenter study, TAM and SALT-M were associated with post-LT mortality but demonstrated limited discriminative accuracy. Candidate high-risk thresholds (TAM ≥3, SALT-M >25) may help identify a small subset of patients with markedly poor post-LT outcomes. However, given their modest performance, these scores should support, not replace, multidisciplinary decision-making, and their applicability should be evaluated in a prospective fashion.
- Open Access
- 11 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70691
Pre‐ TIPS Liver and Spleen Volumetry Are Not Associated With Liver‐Related Outcomes After TIPS Placement for Refractory Ascites
Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) improves survival in refractory ascites. A careful patient's selection is mandatory as TIPS can lead to complications. Liver volumetry is predictive of outcomes before hepatic surgery, but data on its role before TIPS placement are scarce. We aimed to evaluate whether liver and spleen volume measurements are associated with prognosis after TIPS placement in patients with ascites. Methods: We analysed data from three French centers, treated with TIPS between 2017 and February 2022. Inclusion criteria encompassed a TIPS placement for refractory or recurrent ascites and availability of cross‐sectional imaging. Exclusion criteria included non‐cirrhotic portal hypertension, other indications for TIPS, hepatocellular carcinoma beyond Milan criteria, and extrahepatic malignancy. Liver and spleen volumes were measured using pre‐TIPS CT or MRI scans. The primary endpoint was 1‐year transplant‐free survival (TFS). Secondary endpoints were overt hepatic encephalopathy (HE), recurrence of ascites, acute variceal bleeding, and jaundice. Results: The 160 patients were included (median age 60 years, male gender 83.8%, alcohol‐related cirrhosis 58.8%, with active alcohol consumption in 25.6%, Child‐Pugh B cirrhosis in 81.2%, median MELD score was 12). The 1‐year TFS was 60.1%. Multivariate analysis identified serum creatinine (HR = 1.01 95% CI [1.00–1.01], p = 0.04), total bilirubin (HR = 1.02 95% CI [1.02–1.04], p = 0.004), and portal pressure gradient (HR = 1.09 95% CI [1.01–1.18], p = 0.03) as independent factors associated with TFS. Neither liver‐to‐spleen volume ratios (LSVR) ( p = 0.36) nor liver volume index ( p = 0.92) were significantly associated with death or LT. Overall, 38.1% of patients developed overt HE after TIPS, with lower platelet count (HR = 1.01 95% CI [1.00–1.01], p = 0.04) emerging as an independent predictor. No radiological characteristics were associated with the recurrence of ascites. Conclusions: In this multicenter study, liver and spleen volumes were not associated with transplant‐free survival or liver‐related outcomes in patients undergoing TIPS for ascites. These findings suggest that liver volumetry should not be a determining factor in patient selection for TIPS placement.
- 11 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70691
Open AccessPre‐ TIPS Liver and Spleen Volumetry Are Not Associated With Liver‐Related Outcomes After TIPS Placement for Refractory Ascites
Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) improves survival in refractory ascites. A careful patient's selection is mandatory as TIPS can lead to complications. Liver volumetry is predictive of outcomes before hepatic surgery, but data on its role before TIPS placement are scarce. We aimed to evaluate whether liver and spleen volume measurements are associated with prognosis after TIPS placement in patients with ascites. Methods: We analysed data from three French centers, treated with TIPS between 2017 and February 2022. Inclusion criteria encompassed a TIPS placement for refractory or recurrent ascites and availability of cross‐sectional imaging. Exclusion criteria included non‐cirrhotic portal hypertension, other indications for TIPS, hepatocellular carcinoma beyond Milan criteria, and extrahepatic malignancy. Liver and spleen volumes were measured using pre‐TIPS CT or MRI scans. The primary endpoint was 1‐year transplant‐free survival (TFS). Secondary endpoints were overt hepatic encephalopathy (HE), recurrence of ascites, acute variceal bleeding, and jaundice. Results: The 160 patients were included (median age 60 years, male gender 83.8%, alcohol‐related cirrhosis 58.8%, with active alcohol consumption in 25.6%, Child‐Pugh B cirrhosis in 81.2%, median MELD score was 12). The 1‐year TFS was 60.1%. Multivariate analysis identified serum creatinine (HR = 1.01 95% CI [1.00–1.01], p = 0.04), total bilirubin (HR = 1.02 95% CI [1.02–1.04], p = 0.004), and portal pressure gradient (HR = 1.09 95% CI [1.01–1.18], p = 0.03) as independent factors associated with TFS. Neither liver‐to‐spleen volume ratios (LSVR) ( p = 0.36) nor liver volume index ( p = 0.92) were significantly associated with death or LT. Overall, 38.1% of patients developed overt HE after TIPS, with lower platelet count (HR = 1.01 95% CI [1.00–1.01], p = 0.04) emerging as an independent predictor. No radiological characteristics were associated with the recurrence of ascites. Conclusions: In this multicenter study, liver and spleen volumes were not associated with transplant‐free survival or liver‐related outcomes in patients undergoing TIPS for ascites. These findings suggest that liver volumetry should not be a determining factor in patient selection for TIPS placement.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Coopération oncogénique et effets métaboliques de FGF19 dans le carcinome hépatocellulaire
Le carcinome hépatocellulaire (CHC) est la tumeur maligne primitive hépatique la plus fréquente et se situe au 6e et 3ème rang en termes de fréquence et de mortalité liées au cancer, respectivement. La surexpression de FGF19 est un évènement fréquent dans les CHC humains et des molécules ciblant FGF19 ou son récepteur tyrosine kinase dans le foie (Fibroblast Growth Factor Receptor 4 FGFR4) sont en cours d’étude. Chez la souris l’exposition à des concentrations élevées de FGF19 au long cours provoque une tumorigénèse hépatique. Par ailleurs, FGF19 exerce de nombreux effets métaboliques ayant pour conséquence une protection contre l’insulinorésistance. Ainsi, des molécules analogues à FGF19 sont également en cours d’étude pour traitement de maladies métaboliques, comme la stéatohépatite non alcoolique (ou NASH pour Non alcoholic steatohepatitis). Dans ce contexte, notre projet avait pour but de mieux caractériser les effets oncogéniques et métaboliques de FGF19 dans un modèle de souris immunocompétentes.En utilisant la technique de transfection hydrodynamique des hépatocytes, nous avons obtenu des souris C57Bl6/J ayant une expression de FGF19 persistante, avec des concentrations circulantes supra-physiologiques, associée à l’inhibition de la voie de synthèse des acides biliaires. Nous avons découvert chez ces souris un phénotype de diabète insipide, caractérisé par une polydipsie et une dilution des urines persistant dans le temps. Cet effet est similaire à celui qui a déjà été décrit pour FGF21, une molécule appartenant à la même famille que FGF19. Cependant, l’effet de FGF19 est indépendant de FGF21 et est retrouvé également lorsqu’une tumeur surexprimant FGF19 est injectée par voie orthotopique.Par ailleurs, l’expression de FGF19, seule ou avec l’invalidation simultanée de p53 par la technique de CRISPR-Cas9, donne des CHC bien différenciés après 9-12 mois. La combinaison FGF19 avec une surexpression de C-Myc, avec ou sans l’invalidation de p53, induit le développement de volumineuses tumeurs moyennement différenciées apparaissant après 2-3 semaines seulement. La comparaison avec la tumorigenèse déclenchée par C-Myc seul ou par C-Myc/ CRISPR-p53, fait apparaître une coopération entre Myc et FGF19 donnant lieu à l’accélération très significative de l’oncogenèse par FGF19. L’analyse transcriptomique et histologique de ces tumeurs met en évidence une stimulation de la néoangiogénèse par FGF19. Enfin, dans un modèle de régime pourvoyeur de NASH, l’expression tumorale de FGF19 exerce un effet paradoxal : tout en accélérant la croissance tumorale, elle s’accompagne d’une amélioration histologique de la NASH.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Coopération oncogénique et effets métaboliques de FGF19 dans le carcinome hépatocellulaire
Le carcinome hépatocellulaire (CHC) est la tumeur maligne primitive hépatique la plus fréquente et se situe au 6e et 3ème rang en termes de fréquence et de mortalité liées au cancer, respectivement. La surexpression de FGF19 est un évènement fréquent dans les CHC humains et des molécules ciblant FGF19 ou son récepteur tyrosine kinase dans le foie (Fibroblast Growth Factor Receptor 4 FGFR4) sont en cours d’étude. Chez la souris l’exposition à des concentrations élevées de FGF19 au long cours provoque une tumorigénèse hépatique. Par ailleurs, FGF19 exerce de nombreux effets métaboliques ayant pour conséquence une protection contre l’insulinorésistance. Ainsi, des molécules analogues à FGF19 sont également en cours d’étude pour traitement de maladies métaboliques, comme la stéatohépatite non alcoolique (ou NASH pour Non alcoholic steatohepatitis). Dans ce contexte, notre projet avait pour but de mieux caractériser les effets oncogéniques et métaboliques de FGF19 dans un modèle de souris immunocompétentes.En utilisant la technique de transfection hydrodynamique des hépatocytes, nous avons obtenu des souris C57Bl6/J ayant une expression de FGF19 persistante, avec des concentrations circulantes supra-physiologiques, associée à l’inhibition de la voie de synthèse des acides biliaires. Nous avons découvert chez ces souris un phénotype de diabète insipide, caractérisé par une polydipsie et une dilution des urines persistant dans le temps. Cet effet est similaire à celui qui a déjà été décrit pour FGF21, une molécule appartenant à la même famille que FGF19. Cependant, l’effet de FGF19 est indépendant de FGF21 et est retrouvé également lorsqu’une tumeur surexprimant FGF19 est injectée par voie orthotopique.Par ailleurs, l’expression de FGF19, seule ou avec l’invalidation simultanée de p53 par la technique de CRISPR-Cas9, donne des CHC bien différenciés après 9-12 mois. La combinaison FGF19 avec une surexpression de C-Myc, avec ou sans l’invalidation de p53, induit le développement de volumineuses tumeurs moyennement différenciées apparaissant après 2-3 semaines seulement. La comparaison avec la tumorigenèse déclenchée par C-Myc seul ou par C-Myc/ CRISPR-p53, fait apparaître une coopération entre Myc et FGF19 donnant lieu à l’accélération très significative de l’oncogenèse par FGF19. L’analyse transcriptomique et histologique de ces tumeurs met en évidence une stimulation de la néoangiogénèse par FGF19. Enfin, dans un modèle de régime pourvoyeur de NASH, l’expression tumorale de FGF19 exerce un effet paradoxal : tout en accélérant la croissance tumorale, elle s’accompagne d’une amélioration histologique de la NASH.
- Open Access
- 9 January 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101722
Long-term outcomes and temporal trends following liver transplantation for chronic liver disease in the intensive care unit
- 9 January 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101722
Open AccessLong-term outcomes and temporal trends following liver transplantation for chronic liver disease in the intensive care unit
- Open Access
- 23 September 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (12) , 101594
Disparities in transplant access and outcomes after first cirrhosis decompensation in alcohol-related liver disease
- 23 September 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (12) , 101594
Open AccessDisparities in transplant access and outcomes after first cirrhosis decompensation in alcohol-related liver disease
- Top Cited Papers
- 24 July 2025
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 2 (8)
AI-Standardized Clinical Examination Training on OSCE Performance
- 24 July 2025
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 2 (8)
Top Cited PapersAI-Standardized Clinical Examination Training on OSCE Performance
- 7 July 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , 62-71
Long-term outcome following liver transplantation of patients with ACLF grade 3
- 7 July 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , 62-71
Long-term outcome following liver transplantation of patients with ACLF grade 3
- 6 February 2024
- Published by Springer Nature
- Vol. 2769, 77-85
Hydrodynamic Transfection of Hepatocytes for the Study of Hepatocellular Carcinogenesis
Hydrodynamic tail vein injection (HTVi), also called hydrodynamic gene transfer (HGT), is attracting increasing interest for modeling hepatic carcinogenesis. This highly versatile approach reproducibly provides efficient in vivo transfection of hepatocytes with naked DNA. Here, we give an in-depth description of the injection procedure, which is key for the success of the method. HTVi requires the injection of a large volume of a solution containing plasmids into the tail vein of the mouse. The transient right heart overload created by the injection forces the blood to flow back into the hepatic veins, enlarging the endothelial fenestrae and permeabilizing a fraction of hepatocytes for a few seconds. This results in the uptake of plasmids by the permeabilized hepatocytes, giving rise to their in vivo transfection. Including the Sleeping Beauty transposon system among the injected plasmids leads to the stable transfection of a subset of hepatocytes. HTVi is a powerful technique which enables numerous applications in liver cancer biology, such as a study of oncogene cooperation, of tumor heterogeneity, and interaction with the tumor microenvironment. Key words In vivo transfection Hepatocytes Hydrodynamic gene delivery Mouse model Hepatocellular carcinoma
- 6 February 2024
- Published by Springer Nature
- Vol. 2769, 77-85
Hydrodynamic Transfection of Hepatocytes for the Study of Hepatocellular Carcinogenesis
Hydrodynamic tail vein injection (HTVi), also called hydrodynamic gene transfer (HGT), is attracting increasing interest for modeling hepatic carcinogenesis. This highly versatile approach reproducibly provides efficient in vivo transfection of hepatocytes with naked DNA. Here, we give an in-depth description of the injection procedure, which is key for the success of the method. HTVi requires the injection of a large volume of a solution containing plasmids into the tail vein of the mouse. The transient right heart overload created by the injection forces the blood to flow back into the hepatic veins, enlarging the endothelial fenestrae and permeabilizing a fraction of hepatocytes for a few seconds. This results in the uptake of plasmids by the permeabilized hepatocytes, giving rise to their in vivo transfection. Including the Sleeping Beauty transposon system among the injected plasmids leads to the stable transfection of a subset of hepatocytes. HTVi is a powerful technique which enables numerous applications in liver cancer biology, such as a study of oncogene cooperation, of tumor heterogeneity, and interaction with the tumor microenvironment. Key words In vivo transfection Hepatocytes Hydrodynamic gene delivery Mouse model Hepatocellular carcinoma
- Open Access
- 16 January 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (2) , 238-250
FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis
FGF19 hormone has pleiotropic metabolic functions, including the modulation of insulin sensitivity, glucose/lipid metabolism and energy homeostasis. On top of its physiological metabolic role, FGF19 has been identified as a potentially targetable oncogenic driver, notably in hepatocellular carcinoma (HCC). Nevertheless, FGF19 remained an attractive candidate for treatment of metabolic disease, prompting the development of analogs uncoupling its metabolic and tumor-promoting activities. Using pre-clinical mice models of somatic mutation driven HCC, we assessed the oncogenicity of FGF19 in combination with frequent HCC tumorigenic alterations: p53 inactivation, CTNNB1 mutation, CCND1 or MYC overexpression. Our data revealed a strong oncogenic cooperation between FGF19 and MYC. Most importantly, we show that this oncogenic synergy is conserved with a FGF19-analog Aldafermin (NGM282), designed to solely mimic the hormone’s metabolic functions. In particular, even a short systemic treatment with recombinant proteins triggered rapid appearance of proliferative foci of MYC-expressing hepatocytes. The fact that FGF19 analog Aldafermin is not fully devoid of the hormone’s oncogenic properties raises concerns in the context of its potential use for patients with damaged, mutation-prone liver.
- 16 January 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (2) , 238-250
Open AccessFGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis
FGF19 hormone has pleiotropic metabolic functions, including the modulation of insulin sensitivity, glucose/lipid metabolism and energy homeostasis. On top of its physiological metabolic role, FGF19 has been identified as a potentially targetable oncogenic driver, notably in hepatocellular carcinoma (HCC). Nevertheless, FGF19 remained an attractive candidate for treatment of metabolic disease, prompting the development of analogs uncoupling its metabolic and tumor-promoting activities. Using pre-clinical mice models of somatic mutation driven HCC, we assessed the oncogenicity of FGF19 in combination with frequent HCC tumorigenic alterations: p53 inactivation, CTNNB1 mutation, CCND1 or MYC overexpression. Our data revealed a strong oncogenic cooperation between FGF19 and MYC. Most importantly, we show that this oncogenic synergy is conserved with a FGF19-analog Aldafermin (NGM282), designed to solely mimic the hormone’s metabolic functions. In particular, even a short systemic treatment with recombinant proteins triggered rapid appearance of proliferative foci of MYC-expressing hepatocytes. The fact that FGF19 analog Aldafermin is not fully devoid of the hormone’s oncogenic properties raises concerns in the context of its potential use for patients with damaged, mutation-prone liver.
- Open Access
- 7 December 2023
- Published by Wiley in United European Gastroenterology Journal
- Vol. 12 (4) , 429-439
Atezolizumab and bevacizumab for non‐resectable or metastatic combined hepatocellular‐cholangiocarcinoma: A multicentric retrospective study
Backgrounds: The efficacy of atezolizumab/bevacizumab has never been reported in patients with metastatic/unresectable combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA).Patients and Methods: We retrospectively included patients with a histological diagnosis of unresectable/metastatic cHCC‐CCA and treated with atezolizumab/bevacizumab (2020–2022) in 7 centers. Clinical and radiological features were collected at the beginning of atezolizumab/bevacizumab. We reported the radiological response using RECIST criteria, overall survival (OS) and progression‐free survival (PFS).Results: Sixteen patients with cHCC‐CCA were included and were predominantly male (75%) with advanced fibrosis/cirrhosis (69%). Nine patients received atezolizumab/bevacizumab as a first‐line systemic treatment, 5 as a second line, 1 as a third line and 1 as a fifth line. Severe digestive bleeding occurred in 2 patients. Among the 9 patients treated in the first line, 4 experienced radiological progression, 3 partial response and 1 had stable disease. Patients treated with atezolizumab/bevacizumab in the first line had a median OS of 13 months and a median PFS of 3 months. Among the 7 patients receiving atezolizumab/bevacizumab as a second line or more, 4 patients harbored a stable disease, 2 a partial response, and 1 a progressive disease.Conclusions: The combination of atezolizumab and bevacizumab showed signs of anti‐tumor efficacy in patients with unresectable/metastatic cHCC‐CCA.
- 7 December 2023
- Published by Wiley in United European Gastroenterology Journal
- Vol. 12 (4) , 429-439
Open AccessAtezolizumab and bevacizumab for non‐resectable or metastatic combined hepatocellular‐cholangiocarcinoma: A multicentric retrospective study
Backgrounds: The efficacy of atezolizumab/bevacizumab has never been reported in patients with metastatic/unresectable combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA).Patients and Methods: We retrospectively included patients with a histological diagnosis of unresectable/metastatic cHCC‐CCA and treated with atezolizumab/bevacizumab (2020–2022) in 7 centers. Clinical and radiological features were collected at the beginning of atezolizumab/bevacizumab. We reported the radiological response using RECIST criteria, overall survival (OS) and progression‐free survival (PFS).Results: Sixteen patients with cHCC‐CCA were included and were predominantly male (75%) with advanced fibrosis/cirrhosis (69%). Nine patients received atezolizumab/bevacizumab as a first‐line systemic treatment, 5 as a second line, 1 as a third line and 1 as a fifth line. Severe digestive bleeding occurred in 2 patients. Among the 9 patients treated in the first line, 4 experienced radiological progression, 3 partial response and 1 had stable disease. Patients treated with atezolizumab/bevacizumab in the first line had a median OS of 13 months and a median PFS of 3 months. Among the 7 patients receiving atezolizumab/bevacizumab as a second line or more, 4 patients harbored a stable disease, 2 a partial response, and 1 a progressive disease.Conclusions: The combination of atezolizumab and bevacizumab showed signs of anti‐tumor efficacy in patients with unresectable/metastatic cHCC‐CCA.